Atezolizumab,nivolumab,Pembrolizumab,Ipilimumab
merck,roche,bms
['nivo', 'rcc,(-irccs),(-srcc),(-urcc)', 'atezo', 'pembro']
 discusses the adjuvant and perioperative rcc io trials.
given the similar trial designs, fair to say pembro is more active than atezo in rcc.
periop nivo? given confounding factors and 10% drop off at the beginning of the trial, too early to call... #esmo22 
Enjoying oncology, without meaning to sound too cynical